Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials

British Medical Journal

Volumn 328, Issue 7447, 2004, Pages 1046-1050

  Als Nielsen, Bodil ^a   Gluud, Lise L ^a   Gluud, Christian ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMMONIA; ANTIBIOTIC AGENT; DISACCHARIDE; LACTITOL; LACTULOSE; NEOMYCIN; PLACEBO; RIBOSTAMYCIN; RIFAXIMIN; VANCOMYCIN;

ABDOMINAL PAIN; ABSORPTION; AMMONIA BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MORTALITY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

EID: 2342487336     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38048.506134.ee     Document Type: Review

References (45)

1. Gitlin N. Hepatic encephalopathy In: Zakim D, Boyer TD, eds. Hepatology. A textbook of liver disease. Philadelphia: WB Saunders, 1996:605-17.
2. Conn HO, Lieberthal MM. Lactulose in the management of chronic portal-systemic encephalopathy. In: Conn HO, Lieberthal MM, eds. The hepatic coma syndromes and lactulose. Baltimore: William & Wilkins, 1979:323-39.
3. Bircher J, Muller J, Guggenheim P, Hammerli UP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1966;i:890-2.
4. Weissenborn K. Recent developments in the pathophysiology and treatment of hepatic encephalopathy. Baillieres Clin Gastroenterol 1992;6:609-30.
5. Conn HO, Leevy CM, Vlacevic ZR, Rodgers JB, Maddrey WC, Seef L. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573-83.
6. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978;23:398-406.
7. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987;7:1278-84.
8. Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. J Hepatol 1987;4:236-44.
9. Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992;15:222-8.
10. Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic encephalopathy. A meta-analysis. Dig Dis Sci 1993;38:916-22.
11. Morgan MY. Nutritional aspects of liver and biliary disease. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. Oxford: Oxford University Press, 1999:1923-81.
12. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-76.
13. Als-Nielsen B, Kjaergard LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy (protocol for a Cochrane review). In: Cochrane Library, Issue 2. Oxford: Update Software, 2001.
14. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-900.
15. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
16. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Ann Intern Med 2001;135:982-9.
17. Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med 1969;281:408-12.
18. Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970;59:827-32.
19. Rodgers JB Jr, Kiley JE, Balint JA. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol. Am J Gastroenterol 1973;60:459-65.
20. Germain L, Frexinos J, Louis A, Ribet A. Double blind study of lactulose in 18 patients with chronic hepatic encephalopathy after portocaval shunt. Arch Fr Mal App Dig 1973;62:293-302.
21. Corazza GR, Tacconi C, Zoli G, Somarolli M, D'Ambro A, Bernardi M. Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy. Int J Clin Pharmacol Res 1982;2:7-13.
22. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-43.
23. Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997;26:1410-4.
24. Shi H, Liu HY, Fu Z, Zhu L, Chen WZ. Lactitol in treatment of subclinical hepatic encephalopathy: a double blind placebo-controlled randomised trial [in Chinese]. Chinese J Digestion 1997;17:221-3.
25. Li Z, Zhang H, Hong Y. Clinical effect of lactulose in the treatment of subclinical hepatic encephalopathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999;9:13-5.
26. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000;45:1549-52.
27. Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981;26:498-506.
28. Russo M, Galanti B, Nardiello S, Pizzella T, Ronga C, Giusti G. Ribostamycin for the treatment of hepatic encephalopathy: a crossover study with lactulose. Curr Ther Res Clin Exp 1989;45:133-41.
29. Blanc P, Couderc M, Peray P, Liautard J, Larrey D, Michel H, et al. Lactitol venus vancomycin in the treatment of acute hepatic encephalopathy: a double blind, randomized trial [abstract]. Gut 1993;34:46.
30. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-18.
31. Fera G, Agostinacchio F, Nigro M, Schiraldi O, Ferrieri A. Rifaximin in the treatment of hepatic encephalopathy. Rev Eur Etud Clin Biol 1993;4:57-66.
32. Festi D, Mazzella G, Orsini M, Sottili S, Sangermano A, Li B. Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. Curr Ther Res Clin Exp 1993;54:598-609.
33. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double-blind, double dummy study versus lactulose. Eur J Clin Res 1993;4:7-18.
34. Song H, Lee KS, Kim MH, Paik YH, Moon BS, Yoon SH. The clinical efficacy of rifaximin in the treatment of hepatic encephalopathy (comparison with lactulose) [abstract]. Hepatology 2000,32:407.
35. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vicchio BD. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003;49:53-62.
36. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas K, Vargas V. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-8.
37. Jüni P, Altman D, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
38. Weissenborn K. Minimal hepatic encephalopathy: a permanent source of discussion. Hepatology 2002;35:494-6.
39. Conn HO. A clinical hepatologist's predictions about non-absorbed carbohydrates for the early twenty-first century. Scand J Gastroenterol Suppl 1997;222:88-92.
40. Dawson AM, McLaren J, Sherlock S. Neomycin in the treatment of hepatic coma? Lancet 1957;273:1263-8.
41. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-5.
42. Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial. Gastroenterol Clin Biol 1994;18:1063-8.
43. Pocock SJ. The size of a clinical trial. In: Clinical trials: a practical approach. Chichester: John Wiley, 1983:123-42.
44. Piaggio G, Pinol AP. Use of the equivalence approach in reproductive health clinical trials. Stat Med 2001;20:3571-7.
45. Hunter PA. Coping with the rising tide of resistance to antimicrobial agents. Drug News Perspect 2001;14:309-17.